Back to top
more

Novavax (NVAX)

(Delayed Data from NSDQ)

$13.85 USD

13.85
5,432,722

-1.11 (-7.42%)

Updated Jul 19, 2024 04:00 PM ET

After-Market: $13.86 +0.01 (0.07%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.15%
2Buy17.88%
3Hold9.47%
4Sell5.14%
5Strong Sell2.57%
S&P50011.11%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

D Value D Growth F Momentum F VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 28% (71 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Balance Sheet

Research for NVAX

The Zacks Equity Research reports, or ZER for short, are our in-house, independently produced research reports.

The ever popular one-page Snapshot reports are generated for virtually every single Zacks Ranked stock. It's packed with all of the company's key stats and salient decision making information. Including the Zacks Rank, Zacks Industry Rank, Style Scores, the Price, Consensus & Surprise chart, graphical estimate analysis and how a stocks stacks up to its peers.

The detailed multi-page Analyst report does an even deeper dive on the company's vital statistics. In addition to all of the proprietary analysis in the Snapshot, the report also visually displays the four components of the Zacks Rank (Agreement, Magnitude, Upside and Surprise); provides a comprehensive overview of the company business drivers, complete with earnings and sales charts; a recap of their last earnings report; and a bulleted list of reasons to buy or sell the stock. It also includes an industry comparison table to see how your stock compares to its expanded industry, and the S&P 500.

Researching stocks has never been so easy or insightful as with the ZER Analyst and Snapshot reports.

Learn more about Zacks Equity Research reports

See more Zacks Equity Research reports

   

Fiscal Year End for Novavax, Inc falls in the month of December.

All items in Millions except Per Share data.

12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Assets          
Cash & Equivalents 579 1,347 1,527 805 82
Receivables 297 82 455 262 8
Notes Receivable 0 0 0 0 0
Inventories 42 37 0 0 0
Other Current Assets 226 237 174 181 8
Total Current Assets 1,144 1,703 2,155 1,248 97
Net Property & Equipment 306 294 229 180 11
Investments & Advances 0 0 0 0 0
Other Non-Current Assets 0 0 0 0 0
Deferred Charges 0 0 0 0 0
Intangibles 127 126 136 141 57
Deposits & Other Assets 35 28 57 13 8
Total Assets 1,797 2,259 2,577 1,582 173
Liabilities & Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Notes Payable 0 325 0 0 0
Accounts Payable 133 217 127 54 3
Current Portion Long-Term Debt 0 0 0 0 0
Current Portion Capital Leases 5 27 131 106 0
Accrued Expenses 395 591 674 142 20
Income Taxes Payable 0 0 0 0 0
Other Current Liabilities 1,103 1,300 1,459 277 3
Total Current Liabilities 1,635 2,460 2,390 580 26
Mortgages 0 0 0 0 0
Deferred Taxes/Income 622 179 173 0 3
Convertible Debt 168 166 323 322 321
Long-Term Debt 0 0 0 0 0
Non-Current Capital Leases 56 31 0 40 0
Other Non-Current Liabilities 33 56 42 13 10
Minority Interest (Liabilities) 0 0 0 0 0
Total Liabilities 2,514 2,893 2,928 955 359
Shareholders Equity 12/31/2023 12/31/2022 12/31/2021 12/31/2020 12/31/2019
Preferred Stock 0 0 0 0 0
Common Stock (Par) 1 1 1 1 0
Capital Surplus 4,192 3,738 3,352 2,535 1,261
Retained Earnings -4,821 -4,276 -3,618 -1,874 -1,432
Other Equity 3 -6 -1 7 -13
Treasury Stock 92 91 85 42 3
Total Shareholder's Equity -717 -634 -352 627 -186
Total Liabilities & Shareholder's Equity 1,797 2,259 2,577 1,582 173
Total Common Equity -717 -634 -352 627 -186
Shares Outstanding 118.70 78.50 75.60 63.60 32.30
Book Value Per Share -6.04 -8.08 -4.65 9.86 -5.76

Fiscal Year End for Novavax, Inc falls in the month of December.

All items in Millions except Per Share data.

6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Assets          
Cash & Equivalents -99,999 491 579 662 516
Receivables NA 21 297 124 395
Notes Receivable NA 0 0 0 0
Inventories NA 16 42 70 23
Other Current Assets NA 199 226 152 193
Total Current Assets NA 727 1,144 1,007 1,128
Net Property & Equipment NA 291 306 301 300
Investments & Advances NA 0 0 0 0
Other Non-Current Assets NA 0 0 0 0
Deferred Charges NA 0 0 0 0
Intangibles NA 123 127 124 128
Deposits & Other Assets NA 31 35 35 33
Total Assets NA 1,354 1,797 1,657 1,685
Liabilities & Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Notes Payable NA 0 0 0 0
Accounts Payable NA 58 133 102 87
Current Portion Long-Term Debt NA 0 0 0 0
Current Portion Capital Leases NA 6 5 1 1
Accrued Expenses NA 257 395 311 458
Income Taxes Payable NA 0 0 0 0
Other Current Liabilities NA 483 1,103 1,054 1,050
Total Current Liabilities NA 804 1,635 1,469 1,596
Mortgages NA 0 0 0 0
Deferred Taxes/Income NA 841 622 609 607
Convertible Debt NA 168 168 168 167
Long-Term Debt NA 0 0 0 0
Non-Current Capital Leases NA 55 56 53 31
Other Non-Current Liabilities NA 33 37 38
Minority Interest (Liabilities) NA 0 0 0 0
Total Liabilities NA 2,221 2,514 2,336 2,440
Shareholders Equity 6/30/2024 3/31/2024 12/31/2023 9/30/2023 6/30/2023
Preferred Stock NA 0 0 0 0
Common Stock (Par) NA 1 1 1 1
Capital Surplus NA 4,205 4,192 4,067 3,856
Retained Earnings NA -4,969 -4,821 -4,643 -4,512
Other Equity NA -11 3 -12 -8
Treasury Stock NA 94 92 92 91
Total Shareholder's Equity NA -867 -717 -678 -755
Total Liabilities & Shareholder's Equity NA 1,354 1,797 1,657 1,685
Total Common Equity 0 -867 -717 -678 -755
Shares Outstanding 140.40 140.40 118.70 118.70 86.30
Book Value Per Share 0.00 -6.18 -6.04 -5.71 -8.74